Medical and Pharmaceutical Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ This unfortunate incident occurred during a study on the company's Rett syndrome therapeutic NGN-401 Rowan DunneNovember 22, 2024
Cannabis FDA gives long-awaited green light to veterans cannabis trial for PTSD After 3 years of negotiating, a cannabis smoking study with 320 American vets is about to kick off Rowan DunneNovember 20, 2024
Medical and Pharmaceutical GRAIL uses lung cancer blood test to determine who needs post-surgery therapy most The first patient has been screened with the R&D-stage test in a Phase III study Rowan DunneNovember 19, 2024
Health & Wellness Rani Therapeutics enjoys 50% bump on insider buying spree The company focuses on oral delivery of biologics, and may be benefiting from investor speculation Joseph MortonOctober 15, 2024
Medical and Pharmaceutical Scholar Rock stock skyrockets on successful phase 3 trial results The SAPPHIRE study demonstrated statistically significant and clinically meaningful improvements Joseph MortonOctober 7, 2024
Medical and Pharmaceutical Wave Life Sciences shares pop 50% on positive clinical data for common type of muscular dystrophy Duchenne muscular dystrophy is a severe, progressive genetic disorder that primarily affects boys Joseph MortonSeptember 24, 2024
Medical and Pharmaceutical Edgewise Therapetics shares skyrocket on positive clinical trial returns The company stock rose 55 per cent after results of one dose show immediate results Joseph MortonSeptember 19, 2024
Medical and Pharmaceutical Prelude Therapeutics Incorporated shares drop 30% on clinical trial news The drug in question is also presently being tested in an ongoing dose-escalation Phase 1 trial for patients with solid tumours Joseph MortonSeptember 13, 2024
Medical and Pharmaceutical Why are Viridian Therapeutics shares on the rise on Tuesday? Veligrotug’s response rate and metrics suggest competitive, and potentially superior, performance than drug presently on the market Joseph MortonSeptember 10, 2024
Medical and Pharmaceutical AstraZeneca shares slide on disappointing lung cancer drug trial results "Dato-DXd" was thought to have immense potential but now appears to be a disappointment Rowan DunneSeptember 10, 2024